



Demand for measuring estradiol at low concentrations is
increasing, and the widely used ‘direct’ radioimmunoassays that do
not require a preliminary organic purification step may be
inadequate in patient care because of their limited accuracy. In
observational epidemiology, however, the main concern is to obtain
a correct ranking of individuals’ hormone concentration relative to
the true level (as determined through a ‘gold standard’). Despite
differences in the absolute scale of measured and true
concentrations, correct ranking will permit calculation of unbiased
estimates of hormone–disease associations. In prospective
studies, the major concerns are the limited volume of often
irreplaceable specimens and the need to perform a large number
of assays within a reasonable period of time. Organic purification is
often not feasible because of sample volume requirements and
logistic difficulties, and so the development of accurate, rapid and
inexpensive methods to measure sex steroids at low
concentrations would represent a valuable new research tool for
both clinicians and epidemiologists.
A timely commentary by Dowsett and Folkerd [1] in the
January issue of this journal directs attention to the
shortcomings of commonly used direct immunoassays for
estradiol, which are especially problematic when the
analyte’s concentrations are very low [2]. Until recently,
analyses of estradiol at low concentrations would have
been highly unusual, given that the assays were intended
mostly for assessment of reproductive function in
premenopausal women. The situation has greatly
changed, however. In clinical oncology the demand for
low-level determinations has been fueled by the
introduction and ever growing use of aromatase inhibitors.
In research, this need has been stimulated by the
publication of a series of prospective cohort studies [3,4]
offering consistent evidence that breast and endometrial
cancer are associated with measurable, differential
elevations in the extremely low circulating estrogen
concentrations that are typical of older, postmenopausal
women. Bearing in mind the prospect of increasing
demand for measurements of estradiol and other sex
steroids at low concentrations, the nature and extent of
the technical difficulties connected with performing such
determinations should be carefully considered and
addressed.
There is no question that in clinical practice the use of
rapid and inexpensive immunoassays that skip the costly
and time-consuming purification step is hard to justify,
given the likelihood of inaccuracies in measurements,
which may in turn lead to erroneous and possibly harmful
clinical decisions. If one considers the technical issues
that are involved in measuring estradiol at low
concentrations, including competing binding, cross-
reactivity, and matrix effects, it is difficult to dispute the
validity of Dowsett and Folkerd’s warnings. In short, it
seems unjustified and perhaps bordering on the
irresponsible to base clinical decisions in patients
receiving treatment with aromatase inhibitors, or
tamoxifen, on estradiol assays that do not include an
organic extraction step.
Although it is unquestionable that clinical practice
demands high degrees of accuracy that could not be met
with direct immunoassays, a distinction must be made
between the requirements of patient care and those of
observational epidemiologic research. Indeed,
epidemiologists working in the area of endogenous
hormones and cancer are keenly aware of the limitations
of direct assays and have long attempted to address and
clarify the problems connected with their use [5–7]. Key
prerequisites for the selection of laboratory assays for
epidemiologic studies are adequate reproducibility and
accurate ranking of individuals according to long-term
concentrations of the circulating compound of interest [6].
As for sex steroids, direct assays have been found to be
sufficiently reproducible for use in epidemiologic research,
despite the existence of considerable inter-laboratory
variations [2,6,7]. The correlations between measure-
ments obtained by direct and indirect radioimmunoassays
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and between indirect radioimmunoassays and mass
spectrometry, taken as the ‘gold standard’, have also been
reasonably high, at least when direct assays have been
carefully chosen [6,7]. In a validation study in post-
menopausal women from the New York University
Women’s Health Study [6], only two out of the five tested
direct kits for measurement of estradiol exhibited good
correlations with the indirect assays.
However, the standardization of the absolute scale of
assays remains problematic, and it is evident that direct
assays consistently overestimate estradiol or other sex
steroid concentrations. Nevertheless, what matters the
most in epidemiologic research is the measurement’s
relative ranking, which allows the computation of reliable
estimates of relative risk. The results of the Endogenous
Hormones and Breast Cancer Collaborative Group study
[3], which pooled together the data from nine prospective
studies, offer no indication that the magnitude of the
associations between concentrations of several sex
steroid hormones (including estradiol) and breast cancer
risk in postmenopausal women differed markedly
according to the direct or extraction laboratory methods
used. Although these results are reassuring, further
confirmation is necessary.
Reliability and validation assessments of the performance
of direct immunoassays before initiating large-scale
studies of hormone concentrations in precious biologic
specimen should be available in all epidemiologic studies.
Correct scaling of the measurements enhances the
comparability of results between studies and facilitates
pooled analyses of findings, which is a natural step
forward in our efforts to understand hormonal effects on
disease risk and is the most efficient way to combine data
resources and scientific expertise. Furthermore, accurate
estradiol concentrations, in combination with sex hormone
binding globulin measurements, may be used to calculate
the bioavailable fraction of estradiol [6,8,9].
In observational epidemiology, two major issues come into
play, which are almost completely irrelevant in clinical
practice. The first concerns the limited quantity of available
analyte. For example, because hormonal determinations
must be based on samples drawn well in advance of
cancer diagnosis, all of the studies included in the
Endogenous Hormones and Breast Cancer Collaborative
Group [3] – extensively cited by Dowsett and Folkerd [1] –
were case–control studies nested in prospective cohorts.
The common characteristic of this type of study is that
they rely on serum or plasma samples stored for lengthy
periods that are usually available in small, finite volumes.
Although some of the studies were able to use organic
extraction, in normal circumstances the need to preserve
highly valuable, irreplaceable biologic material dictates
that the smallest amount of analyte possible be used. We
believe that, at least until new methods become available,
such a task is best achieved through carefully chosen
direct immunoassays. However, it could be argued that
when multiple steroid assays are to be performed, the
same test material could be used for the organic
extraction and chromatographic separation steps, thus
reducing differences in volume requirements with direct
assays.
A second, equally important issue is that extraction assays
tend to be substantially labour intensive and create
nontrivial logistical complications in research using large
numbers of individuals. An advantage of direct
immunoassays is their relative simplicity, which makes
them amenable to automation and further reductions in
time and costs [6]. A fast automated analysis allows
samples to be thawed and analyzed for several hormones
within a single day, which, in the case of studies involving
quantification of a battery of analytes from various
hormone groups, will reduce the necessity for repeated
thawing of samples and/or preparation of multiple small
volume aliquots, which might increase losses and affect
sample quality.
In conclusion, epidemiologists and laboratory scientists
should continue working together to improve techniques
and strategies that will limit the effect of measurement and
laboratory errors. High priority should be given to
improvement in the accuracy of direct assays and the
sample volume and labour requirements of extraction
assays. Of course, it goes without saying that assays that
are grossly unreliable would lead to excessive
misclassification and misleading results. The effect of
other sources of measurement error, such as those related
to short-, medium- and long-term physiologic variations in
hormone concentrations, sample handling and storage
conditions, should not be forgotten and adequately
accounted for.
In the case of estradiol and postmenopausal breast
cancer, because of the limits imposed by the small volume
of analyte usually available in prospective cohort studies
and other logistical constraints, epidemiologists have
tended to favour the use of direct assays with the
understanding that such methods, although not perfect,
will provide a reasonably good estimate of the underlying
true concentrations. In spite of the possibility that the true
risk associated with estrogen exposure might have been
somewhat underestimated as a result of measurement
error, the substantial impact that the Endogenous
Hormones and Breast Cancer Collaborative Group’s
observations had on our understanding of the role of
estradiol in breast cancer speaks for itself.
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